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ABSTRACT 
The integration of drugs with nanomaterials have received significant interest in the efficient 
drug delivery systems. Conventional treatments with therapeutically active drugs may cause 
undesired side effects and thus, novel strategies to perform these treatments with a 
combinatorial approach of therapeutic modalities are required. In this study, polymethacrylic 
acid coated gold nanoparticles (AuNP-PMAA) which were synthesized with reversible 
addition-fragmentation chain transfer (RAFT) polymerization were combined with 
doxorubicin (DOX) as a model anticancer drug by creating a pH-sensitive hydrazone linkage 
in the presence of cysteine (Cys) and a cross-linker. Drug-AuNP conjugates were 
characterized via spectrofluorimetry, dynamic light scattering and zeta potential 
measurements as well as X-ray photoelectron spectroscopy. The particle size of AuNP-
PMAA and AuNP-PMAA-Cys-DOX conjugate were calculated as found as 104 nm and  
147 nm, respectively. Further experiments with different pH conditions (pH 5.3 and 7.4) also 
showed that AuNP-PMAA-Cys-DOX conjugate could release the DOX in a pH-sensitive 
way. Finally, cell culture applications with Human cervix adenocarcinoma cell line (HeLa 
cells) demonstrated effective therapeutic impact of the final conjugate for both chemotherapy 
and radiation therapy by comparing free DOX and AuNP-PMAA independently. Moreover, 
cell imaging study was also an evidence that AuNP-PMAA-Cys-DOX could be a beneficial 
candidate as a diagnostic agent. 
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INTRODUCTION 
Recently, the use of nanomaterials in drug delivery systems has gained a tremendous 
attraction in the research of the pharmaceutical industry.1 Their usage in drug formulations is 
getting more important due to the limitation by poor penetration of drugs into tumor tissues 
and adverse effects on healthy cells. Since the conventional therapies including 
therapeutically active drug molecule may not generate a selective distribution for a certain 
location on the organism,  undesirable impacts could have been observed in organs and 
healthy tissues. In order to prevent side effects, surface modification strategies become crucial 
because the attachment of targeting moieties to the drug carrier system makes it selective to 
the target tissue or cells.2,3 There are two strategies for obtaining the targeted drug delivery; (i) 
passive targeting and (ii) active targeting. Passive targeting includes the transport of the nano-
carriers, though leaky vasculature of the diseased tissues via convection or passive diffusion 
and this technique reveals the enhanced permeability and retention (EPR) effect of the drug 
carrier systems.4,5 The use of passive targeting may cause the accumulation of the nano-
carriers within long circulation time in solid tumors.6 For being the appropriate candidate to 
use in passive targeting with EPR effect, the nano-carriers should include three important 
properties; first, they should be larger than 10 nm to avoid the filtration by the kidneys and 
should be about 100 nm to avoid the specific capture by the liver. Second, the nano-carriers 
should be non-ionic or anionic in order to avoid the renal elimination. Third, they should be 
recognized by the reticuloendothelial system for not to be phagocytosed.7 Within this strategy, 
many drug delivery systems have been reported, especially with the use of metallic 
nanoparticles, polymers, lipid or surfactant based vesicular carriers.8-12 Active targeting of 
nanoparticles contains peripherally conjugated targeting ligands for enhanced and selective 
delivery. The targeting ligands such as antibodies, folic acid, glycoconjugates or nucleic acids 
like aptamers are important to the mechanism of cellular uptake. Long circulation times will 
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allow for effective transport of the nanoparticles to the tumor site through the EPR effect, and 
the targeting molecule is able to increase endocytosis of the nanoparticles. The internalization 
of nanoparticle drug delivery systems has shown an increased therapeutic effect.13,14
 Those drug delivery systems have been generally constructed for the cancer treatment 
which remains the major common cause of morbidity and mortality throughout the world.15 In 
the treatment of cancers, a combination of several types of therapeutic modalities with distinct 
mechanisms is considered to be a potential strategy.16 Chemotherapy is one of the most 
common therapies employed in oncology. Therefore, newly designed drug delivery systems 
are regarded as a new paradigm in cancer chemotherapy, particularly by creating pH-sensitive 
infrastructures thanks to the feature of lower acidic matrix of cancerous tissue.17 By using this 
prominent information, numerous chemotherapeutic strategies were developed involving a 
pH-dependent conjugation approach.18-20 Concomitantly, novel multifunctional carriers also 
offer combinatorial therapies with this approach. In a related study, Chen et al. designed a 
novel kind of intelligent nanogels which can spatiotemporally control the release of 
doxorubicin and photosensitizers to combine chemotherapy  and photodynamic therapy.21 
 Gold nanoparticles (AuNPs) are emerging as an efficient platform for diagnostic and 
therapeutic purposes since they have several unique features such as chemical inertness, facile 
surface functionalizability, electronic structure amenable for plasmon resonance and optical 
properties suitable as imaging agents.22 On the other hand, in spite of the synthesis of AuNPs 
is well-advanced, sometimes colloidal stability of NPs might create aggregation problems in 
the case of long-term stability. Furthermore, AuNPs are known as nontoxic, however, AuNPs 
with the size of 1.4 nm induced the toxicity of HeLa cells to a greater extent rather than 15 nm 
AuNPs.23 Meanwhile, toxicity of colloidal NPs is also due to the surface chemistry. In regard 
of this situation,  it has to be essential to control precisely the functional groups on the surface 
as well as remove residual contaminants, especially citrate, arising from the particle 
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synthesis.24-26 Therefore, polymer covered AuNPs are considerably in importance under 
favour of contribution of expanded functionalities, composition and charge. To date, several 
studies were reported the AuNPs covered with polyethyleneglycol (PEG),27 hyaluronic acid,28 
chitosan,29 thiolated polyvinylpyrrolidone,30 heparin,31 etc. Additionaly, AuNPs have an 
excellent capability in the radiation therapy. Radiotherapy, which is known as another 
commonly used therapeutic tool for the treatment of half of the cancers is based on the cancer 
tissue damage with the generation of reactive oxygen species (ROS) like hydroxyl radical 
(OH-) and superoxide anion (O-2) upon illumination with X-rays. Beside, gold (atomic 
number, Z = 79) has a better radiation effect than other radiosensitive elements such as carbon 
(Z = 6), gadolinium (Z = 64), and platinum (Z = 78) due to the photoelectric effect of gold.32 
Also, PEG, polysaccharides, poloxamines or poloxamers covered AuNPs were introduced to 
radiation therapy.33 
 Herein, a combined nanoplatform involving both polymethacrylic acid coated AuNPs 
(AuNP-PMAA) and an anti-cancer drug doxorubicin (DOX) was synthesized with a pH-
sensitive hydrazone linkage between cysteine (Cys) modified AuNP-PMAA and DOX. 
Following the succesful preparation of DOX conjugated AuNP which was denoted as "AuNP-
PMAA-Cys-DOX", spectroscopic and physicochemical characterizations and in vitro drug 
release studies were accomplished. AuNP-PMAA-Cys-DOX conjugates were applied for the 
further cell culture studies including cytotoxicity, radiotherapy and cell imaging by using 
Human cervix adenocarcinoma cell line (HeLa). To evaluate the effectiveness of AuNP-
PMAA-Cys-DOX platforms, AuNP-PMAA and free DOX were tested for the compherensive 
comparison. 
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EXPERIMENTAL SECTION 
Reagents. Methacrylic acid (MAA, 99%, contains  250 ppm monomethylether hydroquinone 
(MEHQ) as inhibitor), 2-Cyano-2-propyl benzodithioate (CPBDT, 97%), sodium borohydride 
(NaBH4, 98%, granular, 10-40 mesh) and gold nanoparticle suspension (40 nm) that stabilized 
with citrate  were purchased from Sigma Aldrich Chemical Company (Dorset, UK). MAA 
was passed through a short column of basic alumina in order to remove MEHQ inhibitor prior 
to polymerisation. 4,4’-azobis-(2-methylpropionitrile) (AIBN) was previously synthesised 
within the group. All other reagents and solvents were obtained at the highest purity available 
from Sigma Aldrich Chemical Company (Dorset, UK) and used as received unless stated 
otherwise. Water (H2O, HiPerSolv Chromanorm for HPLC from VWR International, UK) 
was used throughout the study. Dialysis tubes were purchased from Spectrum Laboratories 
(California, USA). Copper coated 3.05mm diameter square carbon film mesh grids were 
purchased from Agar Scientific (Essex, UK). Doxorubicin (DOX), Cysteine (Cys), N-(3- 
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) and sodium 
dodecyl sulfate (SDS) were obtained from Sigma-Aldrich (St. Louis, USA). N-ε-
maleimidocaproic acid hydrazide (EMCH) was obtained from Thermo Fischer Scientific 
(California, USA). Dulbecco's Modified Eagle Medium (DMEM), Penicillin/Streptomycin 
(10,000 UI/mL), L-Glutamine (200 mM). Trypsin/EDTA (0.05% Trypsin; 0.2 g/L EDTA), 
and Phosphate Buffered Saline (PBS) used in cell culture experiments were obtained from 
Lonza (Basel, Switzerland). Fetal Bovine Serum (FBS) was purchased from Biowest (Nuaillé, 
France).   
Synthesis of Poly(methacrylic acid) (PMAA). RAFT polymerization of MAA was carried 
out in the presence of CPDBT as a RAFT agent, AIBN as an initiator in the methanol and 
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water mixture (2:1) at 70 °C for 12 h. A Schlenk tube was charged with MAA monomer (100 
eq), CPDBT (1 eg), AIBN (0.1 eg) and the solvent (3.0 mL) was degassed by gentle bubbling 
of  argon gas for 30 min. The Schlenk tube was sealed properly and the mixed solution was 
allowed to polymerize. After the confirmation of >98% conversion according to gas 
chromatography (GC), the polymerization reaction was stopped by cooling down and 
exposure to the air. Subsequently, the reaction solution was diluted with 3.0 mL of 
tetrahydrofuran (THF) and then purified by precipitation in diethyl ether. After the filtration, 
the obtained polymer was dried in vacuo and characterized via 1H-NMR and N,N-dimethyl 
formamide (DMF) SEC analysis.  
Reduction of the RAFT End Group of PMAA. The RAFT end group of the obtained 
polymer was reduced by the addition of NaBH4 as the reducing agent in the distilled water. 
PMAA homopolymer was added into a 50-mL round-bottom flask with 10 mL water solution 
of 1.0 M NaBH4 and the solution was bubbled for 15 min (molar ratio of NaBH4:dithioester 
end groups was 25:1). After that, the mixture was allowed to react for 2 h. Following 
reduction, the homopolymer solution was dialyzed against to water for 3 days, while changing 
the water at least three times. Finally, it was freeze dried to get the polymer with thiol end 
group. The product was characterized by 1H-NMR and DMF SEC analysis. 
Preparation of PMAA-Substituted AuNPs. The AuNPs solution was centrifuged in order to 
remove the supernatant and then replaced by the same volume of water prior to the PMAA 
functionalization. Terminally thiolated poly(MAA)  (10 mg) was dissolved in 1.0 mL AuNP 
solution and then agitated in the dark for overnight. To remove excess polymer, the solution 
of the AuNP-stabilized PMAA were centrifuged (5470 rpm, 30 min). Following careful 
decantation of the supernatant, the nanoparticles were then redispersed in 1.0 mL of deionized 
water and then the centrifugation and resuspension process was repeated one more cycle. 
	 8	
These synthesized PMAA-Substituted GNPs were characterized by dynamic light scattering 
(DLS), UV/Vis Spectroscopy, thermogravimetric analysis (TGA) and transmission electron 
microscopy (TEM). The PMAA-coated AuNPs were stored at 4 °C for the further study. The 
general scheme of the reactions related to the synthesis of PMAA covered AuNPs was given 
in Scheme 1. 
 
Scheme 1. RAFT polymerization of MAA and formation of PMAA stabilized AuNPs. 
Construction of pH-sensitive AuNP-PMAA-Cys-DOX Bioconjugate. The bioconjugation 
of polymer capped AuNPs is carried out as three main steps. Initially, AuNPs which have 
pendant carboxylic acid (-COOH) groups via PMAA structure were activated with EDC/NHS 
chemistry and covalent amide bonds were generated by adding Cys. For this purpose, the 
mixture of 25 µL PMAA-AuNP (100 mg/mL dissolved in 10 mM phosphate buffer, pH 7.4), 
48.9 mg EDC, 7.2 mg NHS and 250 µL Cys (from 1.0 mg/mL stock solution dissolved in pH 
5.0 MES buffer) was prepared (Vtotal=1500 µL with the addition of MES buffer) and incubated 
for 3 h with 1000 rpm shaking under ambient conditions. After the incubation step, final 
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mixture was dialyzed against pH 7.4 PBS for 2 h. The dialyzed bioconjugate solution was 
treated with DTT (1:0.9 molar ratio of Cys:DTT). This mixture was incubated overnight 
under 1000 rpm shaking and ambient conditions. After the reduction of S-S linkages between 
Cys residues, EMCH cross-linker was added as 3.2 mg and reacted for 2 h at 1000 rpm 
shaking at room temperature. After incubation, the mixture was dialyzed for 6 h against PBS 
pH 7.4. In the final step, DOX (50 µM as the final concentration) was added to the AuNP-
PMAA-Cys (EMCH) solution and incubated for 2 h at 1000 rpm shaking and room 
temperature and final solution was increased to 2.0 mL. The final AuNP-PMAA-Cys-DOX 
conjugate was dialyzed overnight against PBS, pH 7.4. The conjugation steps for the 
formation of pH-sensitive hydrazone linkage in AuNP-PMAA-Cys-DOX were given in 
Scheme 2. 
 
Scheme 2. The conjugation reactions of the AuNP-PMAA-Cys-DOX particles. 
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Characterization.  
 Proton nuclear magnetic resonance (1H-NMR) spectroscopy (Bruker DPX-400) was 
used to determine the chemical structure of the synthesized polymers. Samples were dissolved 
at 10 mg/mL concentration in D2O or DMSO depending on the solubility of the samples. 
 Size-exclusion chromatography (SEC) measurements were conducted on an Agilent 
1260 infinity system operating in DMF with 5.0 mM NH4BF4 and equipped with refractive 
index detector (RID) and variable wavelength detector (VWD), 2 PLgel 5 µm mixed-C 
columns (300×7.5mm), a PLgel 5 mm guard column (50x7.5mm) and an autosampler. The 
instrument was calibrated with linear narrow poly(methyl methacrylate) standards in range of 
550 to 46,890 g/mol. All samples were passed through 0.2 µm PTFE filter before analysis. 
 Gas Chromatography (GC) was used to monitor the monomer conversion for 
homopolymerization of MAA. GC analysis was performed using an Agilent Technologies 
7820A. An Agilent J&W HP-5 capillary column of 30 m x 0.320 mm with a film thickness of 
0.25 mm was used. The oven temperature was programmed as follows: 40 °C (hold for 1 min) 
increase at 30 °C/min to 300 °C (hold for 2.5 min). The injector was operated at 250 °C and 
the FID was operated at 320 °C. Nitrogen was used as carrier gas at flow rate of 6.5 mL/min 
and a split ratio of 1:1 was applied. Chromatographic data was processed using OpenLab CDS 
ChemStation Edition, version C.01.05. 
 Thermal Gravimetric Analysis (TGA) was conducted with a TA Instruments TGA 
Q500 under nitrogen atmosphere using approximately 5.0 mg of the respective sample for the 
analysis. Method settings: heating from 100 to 900 °C with a heating rate of 10 °C/min. UV 
measurements were performed on a PerkinElmer UV/Vis Spectrometer Lambda 35. 
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 Transmission Electron Microscopy (TEM) analysis was carried out on a JEOL 1400 
instrument operating at an acceleration voltage 200 kV. The TEM specimens were made by 
placing a drop of a nanoparticle water suspension on a carbon-coated copper grid. 
 Spectrofluorimetric and X-ray photoelectron spectroscopy (XPS) analysis were carried 
out to confirm the conjugation of AuNP-PMAA particles to DOX, particle size, surface 
charge. Size distribution and zeta potential of AuNP-PMAA-Cys-DOX conjugates were 
measured by a dynamic light scattering (DLS) method with Zetasizer Nano ZS (Malvern 
Instruments Ltd., U.K.) at a scattering angle of 90 using a wavelength of 633 nm and at 25 °C. 
Prior to measurements, the samples (50 µL) were diluted to 1.0 mL with PBS and each 
sample was measured three times. Zeta potential of samples was calculated by the device 
according to Smoluchowski equation. The samples were kept in +4 °C when not in use. 
Fluorimetric and spectroscopic properties of AuNP-PMAA-Cys-DOX were assessed via a 
Varioskan spectrofluorometer (Thermo, Fischer, U.S.A.). XPS analysis (PHI 5000 
VersaProbe, Minnesota, USA) of the final drug-AuNP conjugate was accomplished, too. Prior 
to measurements, AuNP-PMAA-Cys-DOX solution was dried over an ultrasonically cleaned 
indium tin oxide surface. 
In Vitro Drug Release. The in vitro release behavior of DOX-loaded nanoparticles was 
monitored by creating artificial media. pH 7.4 and pH 5.3 (PBS) were used to simulate the 
healthy and cancerous cellular environments, respectively. Dialysis bags containing 0.5 mL of 
sample were submerged in 5.0 mL buffer medium at 37 °C at 100 rpm. To investigate the in 
vitro release profiles of the samples, 0.5 mL of each of the samples was collected at several 
time intervals (0, 30 min and 1, 2, 4, 6, 8, 12, 24, 48, and 72 h) and replaced with an equal 
volume of fresh medium. 
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 The concentration of DOX in the collected samples was determined by fluorescence 
spectroscopy using a standard curve that was generated by the fluorescence properties of 
DOX. Probing the released DOX, the cumulative drug release percentage (Er) was calculated 
according to the following equation: 
Er =𝑽𝒆  𝑪𝒊𝒏!𝟏𝟏  !𝑽𝒐 𝑪𝒏𝑴(𝑫𝒐𝒙)  
 Where M(Dox) represents the amount of DOX in the particles, Vo is the whole 
volume of the release media (Vo = 5.0 mL), Ve is the volume of the replace media (Ve = 0.5 
mL), and Cn represents the concentration of DOX in the nth sample.  
Cell Culture Studies 
 Human cervix adenocarcinoma cell line (HeLa), (American Type Culture Collection) 
was maintained in DMEM supplemented with 10% FBS, 100 UI/mL Penicillin/Streptomycin, 
and 2.0 mM, L-Glutamine at 37 °C in a humidified incubator with 5.0% CO2. HeLa cells were 
sub-cultured at 80% confluency. Following the synthesis of AuNP-PMAA-Cys-DOX 
bioconjugate, cell culture studies, including toxicity, cell imaging and radiosensitivity with 
HeLa cells. 
Cytotoxicity. A cell proliferation assay kit (MTT reagent) was used to determine the changes 
in cell viability of cells treated with samples. To perform the MTT assay, HeLa cells were 
seeded into 96 well plates and incubated until reaching confluence with normal morphology. 
The samples of AuNP-PMAA, DOX and AuNP-PMAA-Cys-DOX with varying 
concentrations were added to wells and then the cell culture plates were placed in a CO2 
incubator for incubation at 37 °C for 2 h. After incubation, the cells were washed to remove 
culture medium. MTT assay on the cell lines was carried out according to standard procedure. 
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The dose-dependent cell viability of bioconjugates was reported as cell viabilities relative to 
the control (untreated) cells. 
Cell Imaging. In order to observe the interactions of the constructed AuNP-PMAA-Cys-DOX 
bioconjugates and free DOX with HeLa cells, 100 µL of samples were introduced into the 
cells grown in a chamber slide for two days. The cell images were taken by a fluorescence 
microscope (Olympus BX53F) equipped with a CCD camera (Olympus DP72). Following the 
treatment for 2 h at 37 °C in CO2 incubator, the cells were rinsed twice with PBS. Cell images 
were given by merging with phase-contrast images of cells and fluorimetric images of free 
DOX and bioconjugates. 
Radioactivity. In the radiotherapy study, HeLa cells were treated with  commercial AuNP (40 
nm), AuNP-PMAA, free DOX and AuNP-PMAA-Cys-DOX for 24 h, followed by irradiation 
with 2.5, 5.0 and 10 Gray (Gy) using a 6 MV linear accelerator system (LINAC, Siemens 
Primus, Germany). 4,000 cells/well were incubated at 96-well cell culture plate for 24 h under 
standard culture conditions. Then, medium was removed and AuNP, AuNP-PMAA and 
AuNP-PMAA-Cys-DOX (250 μg/mL and the equivalent of 5.0 µM DOX for the final 
conjugate), free DOX (5.0 µM) were applied for 2 h.  A control group was added with no 
sample treatment for the comparison. After radiation treatment, cells were incubated for 72 h 
and cell viability was assessed via the MTT method described above. 
Statistical Analysis. Statistical analyses were conducted using GraphPad Prism software 
(GraphPad Software, La Jolla, CA, U.S.A.). Data were evaluated using one-way analysis of 
variance with Tukey’s multiple comparison post-test. Comparisons with p < 0.05, p<0.01 and 
p<0.001 were considered as statistically significant. 
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RESULTS AND DISCUSSION 
Synthesis of AuNP-PMAA. The homopolymerization of MAA has been achieved with a 
good control due to a narrow polydispersity index with high molecular weight via RAFT 
polymerization. The polymerization reaction was performed in methanol:water at 70 °C for 12 
h. After the purification, DMF SEC analysis based on PMMA standards revealed a single 
peak with an apparent Mn  = 12.1 kg/mol and Mw /Mn = 1.18 (Figure 1). The polymerization 
conversion was calculated using GC and 1H NMR by comparing the integrated signal 
intensity due to the aromatic hydrogen atoms of the RAFT agent at 7.8–7.9 ppm with that due 
the vinylic protons of MAA at 5.8–6.2 ppm. Both characterizations revealed that conversion 
reached ≈ 96%. A small amount of tailing was detected in according to SEC analysis. The 
possible reason of that could be an interaction of carbocyclic acid moieties of the 
homopolymer and SEC column packed materials. Moreover, the Mn by SEC is slightly higher 
than the theoretical molecular weight mainly due to the different structure of PMAA with 
PMMA calibration standard and tailing. The theoretical number average molecular weight, 
Mn(Theo), was calculated as 8.5 KDa by using  (Mn(Theo) = ([M]o/[RAFT]o x conversion x MMAA) + 
MRAFT equation where [RAFT]o is the initial RAFT concentration, [M]o is the initial monomer 
concentration, MMAA is the monomer molecular weight and MRAFT is the RAFT agent 
molecular weight.  
Reduction of the RAFT End Group of PMAA. The RAFT agent terminal group of PMAA 
was reduced to thiol-terminal one in order to immobilize PMAA onto gold nanoparticles in 
the presence of aqueous NaBH4. 1H NMR and SEC were used to analyze the homopolymer 
before and after the reduction.  
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Figure 1. A) SEC analysis via RI detector; B) via VWD; C) 1H NMR characterization of the 
synthesized PMAA homopolymer before and after the reduction of the RAFT terminal group.  
The disappearance of the aromatic protons of the RAFT agent at 7.8–7.9 ppm after being 
treated indicated that all end groups in the CPDB units have been reduced. As depicted in 
Figure 1, no obvious change in the SEC traces was observed and the molecular weight was 
similar to that of before treatment in according to RI detector of SEC. However, Variable 
Wavelength Detector (VWD) of SEC at 308 nm did not show any significant peak after 
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treatment (Figure 1) indicating that the PMAA-SH chains were successfully obtained. In 
contrast, an intense UV signal associated with PMAA-RAFT terminal polymer elution was 
observed. 
Preparation of PMAA-Substituted GNPs. Prior to the PMAA functionalization, the AuNPs 
solution was centrifuged. The supernatant was removed and replaced by the same volume of 
water. Then, PMAA coated gold nanoparticles were prepared by mixing PMAA and AuNPs 
in the dark for overnight. Firstly, the obtained PMAA-coated AuNPs were characterized via 
DLS and UV/Vis Spectroscopy in terms of the investigation of the size and surface plasmon 
resonance maximum band (SPRmax) value change. The SPRmax band of AuNPs is usually in 
according to the nanoparticle size, shape, aggregation and also their dielectric environment. 
As seen in Figure 3, the position of the SPRmax band shifted from 519 to 521 nm due to 
adsorption of PMAA on the surface. Moreover, UV absorbance peak confirmed that the 
AuNPs coated with thiol-terminated PMAA were still spherical in shape and also did not 
show any aggregation due to not any large broad shift in the UV absorbance. 
 PMAA-Substituted GNPs were characterized in terms of the size and zeta potential by 
using DLS. There was a significant increase in the hydrodynamic volume between AuNPs 
and PMAA-AuNP, indicating successful immobilization of PMAA onto the surface. As 
depicted in Figure 2, the size of the gold nanoparticles after the coating with PMAA increased 
from 55.7±0.2 nm to 104±0.7 nm with polydispersity index (PDI) as 0.15, signifying a narrow 
particle size distribution. Moreover, the magnitude of the negative zeta potential increased 
from -26.9±0.2 mV to -43.6±0.8 mV due to the deprotonation of the carboxyl group 
(RCOOH↔ RCOO- + H+) in aqueous solution. According to TEM images, the size of 
PMAA-coated gold nanoparticles ranged between 52±1.4 and 65±2.6 nm. The average size of 
the monodisperse nanoparticles was calculated as 57±1.8 nm. 
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Figure 2. TEM images of the obtained PMAA-coated AuNP and DLS measurement of 
AuNPs and PMAA-coated AuNP. 
 In order to determine the amount of the PMAA polymer immobilized onto AuNPs, 
TGA was performed to analyze each materials thermal profile. As seen in Figure 3, PMAA-
coated AuNP exhibited mass loss until approximately 650 °C due to the decomposition of the 
PMAA polymer onto the surface and the remaining fraction was the Au core of the 
synthesized nanoparticles that was unaffected at temperature as high as 650 °C. It was 
observed that PMAA substituted AuNPs contained 87.4% of the polymer. 
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Figure 3. UV/Vis Spectroscopy characterization of AuNPs and PMAA-coated AuNP and 
TGA measurements of AuNPs, PMAA and PMAA-coated AuNP, respectively. 
Synthesis and Characterization of AuNP-PMAA-Cys-DOX. Following the successful 
synthesis of polymethacrylic acid coated AuNPs, a covalent binding strategy between AuNP-
PMAA and Cys via EDC/NHS chemistry was applied to create a host structure for 
constructing a pH-sensitive bond between AuNP-PMAA-Cys and DOX in PBS and under 
ambient conditions.  
 As the initial characterization step of AuNP-PMAA-Cys-DOX conjugate, the 
spectrophotometric properties were investigated. The fluorescence and UV-vis spectra of 
conjugate were illustrated in Figure 4. To compare the spectral features of DOX before and 
after conjugation procedure, free DOX was also used at the same concentration in AuNP-
PMAA-Cys-DOX conjugate. As revealed in Figure 4A, DOX could show its fluorescence 
emission at 600 nm (ex: 480 nm) while it was conjugated to AuNP-PMAA-Cys. Herein, the 
DOX conjugation was proved with the decrease of fluorescence intensity and absorption 
peaks which was caused by the conjugation steps. In the other studies, similar cases showed 
up as demonstrated in Du et al.34 and Shantni et al.35 by conjugation of polymer-quantum dots 
and PEGylated palladium nanoparticles. However, DOX could protect its spectral properties 
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in the visible area, thereby this issue could be beneficial in calculating the binding efficiency 
(BE %) of DOX to AuNP-PMAA particles. Hence, a standard curve was generated in the 
concentration range of 2.5 - 100 µM DOX with an equation of y = 0.0068x + 0.012  
(R2 = 0.999) by reading the absorbance at 480 nm. Then, the freshly synthesized 1.25 mg/mL 
AuNP-PMAA-Cys-DOX conjugate was measured and the repeatable results showed that Cys 
extended and polymer coated AuNPs could bind 25.5 µM of DOX. Therefore, the BE was 
calculated as 51% by using the following formula; 
BE % = (DOX concentration in conjugate/ Total DOX concentration) x 100. 
 
Figure 4. (A) Spectrophotometric characterization of 1.25 mg/mL AuNP-PMAA-Cys-DOX  
bioconjugate (red lines; containing 25 µM DOX) and 25 µM free DOX (black lines); (B) 
Particle size and (C) zeta potential analysis of AuNP-PMAA-Cys-DOX. 
 After the spectroscopic characterization of AuNP-PMAA-Cys-DOX conjugate, 
another physicochemical parameter was investigated in terms of particle size and zeta 
potential (Figure 4B and 4C). The hydrodynamic particle sizes of AuNP-PMAA and AuNP-
PMAA-Cys-DOX were assessed as 104±0.7 nm (polydispersity index (PDI): 0.15) and 
147±25 nm (PDI: 0.43), respectively. According to the subsequent zeta potential analysis, the 
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surface charges of AuNP-PMAA and AuNP-PMAA-Cys-DOX were assessed as -43.6±0.8 
mV and -22.7±12 mV, respectively. Expectedly, the hydrodynamic particle size of AuNP-
PMAA was increased after the DOX conjugation. Moreover, the negative surface charge 
formed from the -COOH side groups of PMAA was decreased by covering the surface with 
Cys and DOX. It is known that negatively surface charged NPs demonstrate a reduced plasma 
protein adsorption and low rate of nonspecific cellular uptake.36,37 Additionally, the charged 
NPs can repel one another to overcome the natural tendency of aggregation of NPs.38 Hence, 
it can be claimed that newly synthesized AuNP-PMAA and their DOX conjugated forms 
could be suitable for the accumulation in the cancerous tissue by EPR effect thanks to their 
good dispersion stability which was supported by PDI values.  
 In addition to the physicochemical parameters, XPS of the AuNP-PMAA-Cys-DOX 
was employed to observe the demand typical bonds of the final conjugate via the binding 
energies. XPS spectrum in Figure 5 illustrates the detailed information about the crucial bonds 
which were used in the conjugation steps, including an amide bond between carboxyl residues 
of AuNP-PMAA and amino group of Cys and hydrazone as the pH-sensitive linkage. In the 
spectra, the binding energy of 282.65 eV reveals the typical C-C bonds. Normally, C-C 
binding energy shows itself approximately 284 eV.39,40 However, it was proved that 
chemisorption of carbon over a surface could show its binding energy at 282.6 eV.41 In 
addition, amide bond of O=C-N reveals itself at 287.18 eV with a shift and binding energy of 
285.8 presents the typical hydrazone linkage (C=N) as detected in previous studies.42,43 
Furthermore, a small shoulder at 288.5 eV of binding energy shows the RCOO- groups which 
might come from the Cys residues or non-conjugated carboxyl group over PMAA.44 
	 21	
 
Figure 5. XPS scan of C1s of AuNP-PMAA-Cys-DOX conjugation. 
In Vitro Drug Release. In addition to the characterization steps, in vitro release profiles of 
DOX-conjugated polymer coated AuNPs were generated in order to investigate the potential 
use of these particles as delivery carriers. One of the main characteristic feature of tumor sites 
is that having the slightly-acidic microenvironment.45 Therefore, the current study was aimed 
to generate a pH-sensitive DOX conjugation using the AuNP-PMAA as a vehicle in the use of 
chemotherapeutic approaches. Many of the pH-sensitive bonds between a drug and a carrier 
which are formed from a typical hydrazone linkage were evaluated at pH 5.3 as modelling the  
extracellular pH environment of cancer cells and at pH 7.4 as modelling the environment of 
healthy cells.46 As depicted in Figure 6, free DOX was illustrated the typical release profile at 
pH 5.3 by reaching 100% release. On the other hand, it was seemed that the cumulative 
release profile of AuNP-PMAA-Cys-DOX conjugate was more controllable at pH 5.3 
according to the free DOX release (Figure 6). Concomitantly, a similar case was also 
observed at pH 7.4. DOX release from the conjugate at pH 7.4 was about 6.0% up to 72 h. 
This valuable data demonstrated the potential of AuNP-PMAA-Cys-DOX with a slowly-
sustained release and usability for a long-time by keeping the formulation at lower 
temperatures. 
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Figure 6. Cumulative drug release profiles of free DOX at pH 7.4 and AuNP-PMAA-Cys-
DOX bioconjugates at pH 5.3 and pH 7.4 for 72 h at 37 °C.  
Cell Culture. Following the successful characterization steps and defining the release profile 
of DOX in artificial media modelling the extracellular conditions of cancer cells, in vitro cell 
culture techniques were used to evaluate the effects of the final DOX conjugate by comparing 
free DOX and AuNP-PMAA alone with the same concentrations as conjugate. In this manner, 
cytotoxicity, radiosensitive effect and cell imaging studies were performed during cell culture 
experiments. Due to the therapeutic efficacy of DOX and unique radiosensitive activity of 
AuNPs, a combined modality which is conducted with passive targeting strategy was enabled 
within bioimaging of HeLa cells within the fluorescence properties of DOX molecule. The 
related results are given below by discussing the experiments, comparatively.  
Cytotoxicity. Before the evaluation of other parameters with HeLa cells as the model cancer 
cell line in this work, the dose-dependent viability of the cells were determined for AuNP-
PMAA, DOX and AuNP-PMAA-Cys-DOX conjugate for 24 h at 37 °C and 5.0% CO2 under 
humidified conditions. Up to date, it is known that AuNPs do not have much toxic effect upon 
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both cancer and healthy cell lines as illustrated in our previous works.47,48 In this step, AuNP-
PMAA structures were initially tested for their influence upon the viability of HeLa cells. 
Figure 7A represents the effect of polymer coated AuNP particles on cell viability. It can be 
clearly said that polymer coated AuNPs do not exhibit any toxic effect on HeLa cells up to 
500 µg/mL particles (84%). As shown in the Figure 7B, the cell viability profile of free DOX 
is close to AuNP-PMAA-Cys-DOX up to 1.0 µM DOX (equivalent to 50 µg/mL AuNP-
PMAA for conjugate). Although DOX was seemed more effective until 5.0 µM, there was a 
significant decrease between free DOX (47.11%) and AuNP-PMAA-Cys-DOX (25.6%) in the 
final concentration (p<0.001). It is known that the delivery of free DOX is based on simple 
diffusion across the cell membrane. Besides, the uptake of many nanocarriers are based on 
different endoctyic pathways depending on the cell type and the physicochemical properties 
of nanocarrier.49 After the uptake of the functional particles, the particles get cleaved in the 
cells and therapeutic molecules are delivered in the slightly acidic conditions. Since the in 
vitro DOX release profile presented the similar behaviour like other studies, the effect of this 
profile also can give idea for the cytotoxicity. Moreover, it is always showed that free DOX 
can release easily under acidic conditions in the cumulative drug release profiles. However, 
the nanocarrier systems get more effective in the 24 h toxicity tests. In our case, we could 
observe the effective concentration of the proposed theranostic platform as 5.0 µM DOX 
concentration. Hence, the constructed DOX conjugate with a pH-sensitive bond may be a 
good potential in the chemotherapy thanks to its sustained release and having a non-toxic 
carrier architecture.  
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Figure 7. The dose-dependent toxicity of AuNP-PMAA (A), AuNP-PMAA-Cys-DOX and 
free DOX (B) for HeLa cells. Error bars mean ± standard deviation, (n = 4). 
Radioactivity. Radiation therapy is one of the most commonly used treatment modality for 
cancer disease by giving ionizing radiation. It was reported that the effect of ionizing radiation 
could be enhanced within the addition of high-Z materials, including heavy elements such as 
gold, cis-platin etc.50 Beside this, there may be some difficulties related to the radiotherapy 
resulting from the acquired radiation resistance. This limitation opens the doorway of the 
required multiple/combined approaches such as simultaneous applications of drug 
formulations or treatment modalities like photodynamic therapy/radiotherapy as demonstrated 
in our previous report.51 Accordingly, the combination of chemotherapy and radiotherapy by 
using the enhancers of both modalities, AuNP and DOX were conjugated in a facile and 
efficient way by creating a pH-sensitive hydrazone linkage. To investigate the radiosensitive 
effects of AuNP-PMAA-Cys-DOX conjugation, HeLa cells were treated with three different 
ionizing radiation (2.5, 5.0 and 10 Gray). In addition, free DOX (5.0 µM), AuNP-PMAA and 
citrate coated AuNP (as the same concentration with both AuNP-PMAA and AuNP-PMAA in 
conjugate) were compared with AuNP-PMAA-Cys-DOX (equivalent to 5.0 µM) , 
comprehensively.  As shown in Figure 8, 5.0 Gray of ionizing radiation for AuNP-PMAA-
Cys-DOX (27%) demonstrated a significant difference among free DOX (40%), AuNP-
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PMAA (36.3%) and also citrate coated AuNPs (46%) by comparing other doses (p<0.05). 
Meanwhile, DOX was applied to cancer cells in a reported work which supports our 
findings.52 In the irradiation of 2.5 and 10 Grays, it is shown that the cell viabilities of the 
samples ranging from citrate capped AuNPs to AuNP-PMAA-Cys-DOX gave similar results. 
These results were also compared statistically, however as can be seen from the figure, there 
is no dramatic change between applied samples for both irradiation doses. Furthermore, the 
free DOX concentation of 5.0 µM did not present any additional therapeutic effect at 2.5 
Gray. The cell viability of that sample is similar to cytotoxicity test. Within the increase of 
irradiation level, both AuNP-PMAA and DOX created a significant effect according to the 
control group. As mentioned in introduction part, the radiosensitive effect of AuNPs could 
demonstrate in this study, clearly. Expectedly, AuNP-PMAA-Cys-DOX particles were able to 
enhance the therapeutic efficacy comparable to free DOX upon HeLa cells under irradiation 
of 5 Gray. In other reported studies, DOX was used as a radiosensitizer for HeLa cells and 
V79 hamster cell line.53,54 Jagetia and Nayak carried out their research for irradiation effect of 
DOX by introducing 10 µg/mL (equals to 5.8 µM) DOX to HeLa cells between the range of 0 
- 3.0 Gray irradiation doses.53 According to this study, increasing irradiation doses enabled a 
gradual decline in the cell survival compare to control cells without DOX. These results also 
supports our findings related to the decrease in cell viabilities of free DOX group. As 
showned in those studies, the high irradiation doses like 10 gray might cause reduced cell 
viability for control groups without therapeutic molecules. However, samples could 
significantly show their toxicity upon HeLa cells at 10 Gray, when compare to control group 
only (p<0.001). 
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Figure 8. Radiosensitivity effect of uncoated AuNP, AuNP-PMAA, free DOX and AuNP-
PMAA-Cys-DOX at different ionizing radiations (2.5, 5.0 and 10 Grays).  
Cell Imaging. As the final study for the synthesized AuNP-PMAA-Cys-DOX, nontoxic 
concentrations of conjugates were applied to HeLa cells for 2 h to monitor the internalization 
of DOX conjugates. As can be seen from the Figure 9, DOX in conjugate could easily localize 
in the nucleus of HeLa cells as free DOX. Beside fluorescent imaging with the unique 
spectroscopic properties of DOX, phase-contrast images were taken to overlap the images and 
to show that polymer coated AuNP conjugate was also effective in monitoring the cells. This 
capability of the proposed conjugate reveals that it may be a suitable and beneficial candidate 
as a theranostically engineered nanoparticle. 
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Figure 9. Imaging of HeLa cells with phase-contrast and fluorescence technique. Images 
were obtained after treatment of the cell with free DOX and AuNP-PMAA-Cys-DOX 
conjugate for 2 h at 37 °C and 5.0% CO2 atmosphere, under humidity. Images of samples 
were taken with a red filter of fluorescence set up with 100x magnification.  
CONCLUSION 
 We have examined the functional PMAA coated AuNPs which were prepared with 
RAFT polymerization by conjugating with DOX in a pH-sensitive manner. Increasing of the 
particles sizes and decreased surface charges were evidently demonstrated in the 
characterization step besides fluorimetric characterization. Furthermore, AuNP-PMAA with 
51% DOX binding capacity has shown a sustained drug release in the simulated extracellular 
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matrix conditions by differentiating the pH to prove the pH-sensitive property of AuNP-
PMAA-Cys-DOX conjugation. Another considerable influence of the AuNP-PMAA-Cys-
DOX was that this novel platform could be used effectively for the treatment of cancer with 
chemotherapy and radiotherapy modalities when compared only polymer covered AuNPs and 
DOX. In the final step, we illustrated the capability of this conjugate for cell imaging due to 
the fluorescence of DOX. Thereby, AuNP-PMAA-Cys-DOX can be a satisfactory theranostic 
tool in the combined treatment of chemotherapy/radiotherapy and fluorescence imaging.  
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